A Phase 2 interventional study of Alcohol and Sham control in Hypertension and Hypertension,Essential, sponsored by Ablative Solutions, Inc.. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Ablative Solutions, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Essential Hypertension with a site in Belgium — 1 open to participants now, 3 under way, none of them phase 3. Essential Hypertension · Belgium.
Among the 14 studies in Essential Hypertension with a site in Belgium, this one is the 8th largest by enrollment, is one of 3 that started in 2018, is one of 3 in phase 2, and was the 11th registered.
480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →1 of the 14 studies in Essential Hypertension with a site in Belgium is open now. Recruiting first, the newest first:
Orchestra BioMed, Inc · Sites in Belgium, United States, Australia and 12 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 144 across 406 interventional studies indexed under Essential Hypertension.
Median enrollment 394 across the 14 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 10 most frequent:
Ablative Solutions, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Ablative Solutions, Inc. has 2 studies filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
1 of the studies in Essential Hypertension with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Essential Hypertension with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
This study's enrollment of 350 is above the median of 144 across 406 interventional studies indexed under Essential Hypertension.
Browse Essential Hypertension studies →Ablative Solutions, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
Drug: Alcohol
Only renal angiography performed
Other: Sham control
Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
endovascular, renal angiography
Changes in Systolic Ambulatory Blood Pressure
Change from baseline in mean 24-hour ambulatory systolic blood pressure
Time frame: Baseline to 8 weeks post-treatment
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months
Change from baseline in mean 24-hour ambulatory systolic blood pressure from baseline to 6 months
Time frame: 6 months
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months
Change from baseline in mean 24-hour systolic blood pressure at 12 months post-procedure
Time frame: 12 months
Change in Office SBP at 8 Weeks
Change from Baseline in mean office SBP to Week 8
Time frame: 8 weeks
Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 8 Weeks
Change from baseline in mean 24-hour ambulatory diastolic blood pressure and 8 weeks post-procedure
Time frame: 8 weeks
Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 6 Months
Change from baseline in mean 24-hour ambulatory diastolic blood pressure at 6 months post-procedure
Time frame: 6 months
Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 12 Months
Change from baseline in mean 24-hour diastolic blood pressure 12 months post-procedure
Time frame: 12 months
Number of Participants With Major Adverse Events (MAEs)
Number of participants with major adverse events (MAEs) 30 days post-procedure
Time frame: 30 days post procedure
Use of Antihypertensive Medication(s)
Use of antihypertensive medication at 8 weeks
Time frame: 8 weeks
Change in Mean Daytime Ambulatory Systolic Blood Pressure at 8 Weeks
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 8 Weeks
Time frame: 8 weeks
Change in Mean Daytime Ambulatory Systolic Blood Pressure at 6 Months
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 6 Months
Time frame: 6 months
Change in Mean Daytime Ambulatory Systolic Blood Pressure at 12 Months
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 12 Months
Time frame: 12 months
Mean Daytime Ambulatory Diastolic Blood Pressure
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 8 Weeks
Time frame: 8 weeks
Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 6 Months
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 6 months
Time frame: 6 months
Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 12 Months
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 12 Months
Time frame: 12 months
Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 8 Weeks
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 8 Weeks
Time frame: 8 weeks
Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 6 Months
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 6 Months
Time frame: 6 months
Change in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months
Time frame: 12 months
Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 8 Weeks
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 8 weeks
Time frame: 8 weeks
Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 6 Months
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 6 Months
Time frame: 6 months
Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 12 Months
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 12 Months
Time frame: 12 months
Change in Mean Office SBP at 6 Months
Change from Baseline in mean office SBP to 6 Months
Time frame: 6 months
Change in Mean Office SBP to 12 Months
Change from Baseline in mean office SBP to 12 Months
Time frame: 12 months
Change in Mean Office DBP to 8 Weeks
Change from Baseline in mean office DBP to 8 Weeks
Time frame: 8 weeks
Change in Mean Office DBP to 6 Months
Change from Baseline in mean office DBP to 6 Months
Time frame: 6 months
Change in Mean Office DBP at 12 Months
Change from Baseline in mean office DBP to 12 Months
Time frame: 12 months
| Milestone | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Started | 56 | 50 |
| Completed | 44 | 43 |
| Not completed | 12 | 7 |
| Withdrew: Not receiving bilateral treatment or an unsuccessful procedure | 0 | 2 |
| Withdrew: Receiving antihypertensive medications prior to evaluation of the primary abpm | 8 | 4 |
| Withdrew: Not completing the primary abpm | 3 | 1 |
| Withdrew: Not meeting inclusion/exclusion criteria | 1 | 0 |
Change from baseline in mean 24-hour ambulatory systolic blood pressure
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Changes in Systolic Ambulatory Blood Pressure | -1.4 ± 8.6 | -2.9 ± 7.4 |
Change from baseline in mean 24-hour ambulatory systolic blood pressure from baseline to 6 months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean 24-Hour Ambulatory Systolic Blood Pressure | 135.1 ± 11.7 | 134.1 ± 11.6 |
| Change from baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure | -13.4 ± 12.9 | -13.9 ± 11.6 |
Change from baseline in mean 24-hour systolic blood pressure at 12 months post-procedure
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean 24-hour SBP | 133.7 ± 11.3 | 137.6 ± 11.4 |
| Change from baseline in mean 24-hour SBP | -15.9 ± 13.1 | -10.6 ± 11.5 |
Change from Baseline in mean office SBP to Week 8
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Office SBP | 160.6 ± 16.3 | 155.4 ± 14.3 |
| Change from Baseline in mean office SBP | 0.63 ± 13.24 | -4.0 ± 12.6 |
Change from baseline in mean 24-hour ambulatory diastolic blood pressure and 8 weeks post-procedure
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean 24-hour ambulatory diastolic blood pressure | 91.0 ± 6.8 | 92.2 ± 7.6 |
| Change from baseline in Mean 24-hour ambulatory diastolic blood pressure | -1.1 ± 6.6 | -2.0 ± 5.1 |
Change from baseline in mean 24-hour ambulatory diastolic blood pressure at 6 months post-procedure
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean 24-hour ambulatory diastolic blood pressure | 83.4 ± 9.0 | 83.0 ± 8.4 |
| Change from baseline in Mean 24-hour ambulatory diastolic blood pressure | -8.0 ± 8.5 | -9.3 ± 6.9 |
Change from baseline in mean 24-hour diastolic blood pressure 12 months post-procedure
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean 24-hour ambulatory diastolic blood pressure | 81.0 ± 7.9 | 85.6 ± 8.7 |
| Change from baseline in Mean 24-hour ambulatory diastolic blood pressure | -9.8 ± 8.3 | -7.3 ± 7.5 |
Number of participants with major adverse events (MAEs) 30 days post-procedure
| Participants | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Number of Participants With Major Adverse Events (MAEs) | 1 | 1 |
Use of antihypertensive medication at 8 weeks
| medications | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Use of Antihypertensive Medication(s) | 0.089 ± 0.288 | 0.060 ± 0.240 |
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 8 Weeks
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Daytime Ambulatory Systolic Blood Pressure | 153.2 ± 12.0 | 150.6 ± 10.5 |
| Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure | -1.7 ± 9.9 | -3.2 ± 9.5 |
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 6 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Daytime Ambulatory Systolic Blood Pressur | 140.6 ± 12.3 | 139.7 ± 12.8 |
| Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 6 Months | -14.5 ± 13.7 | -14.0 ± 13.3 |
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 12 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Daytime Ambulatory Systolic Blood Pressure | 140.1 ± 12.1 | 143.5 ± 12.6 |
| Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure | -15.5 ± 13.6 | -10.5 ± 12.8 |
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 8 Weeks
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Daytime Ambulatory Diastolic Blood Pressure | 94.7 ± 9.7 | 95.2 ± 7.5 |
| hange from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure | -1.4 ± 6.8 | -2.3 ± 6.8 |
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 6 months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Daytime Ambulatory Diastolic Blood Pressure | 87.6 ± 9.0 | 87.8 ± 9.2 |
| Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure | -8.9 ± 8.6 | -9.3 ± 8.9 |
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 12 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Daytime Ambulatory Diastolic Blood Pressure | 86.0 ± 8.7 | 90.4 ± 9.6 |
| Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure | -9.5 ± 8.7 | -7.6 ± 8.9 |
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 8 Weeks
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Nighttime Ambulatory Systolic Blood Pressure | 136.9 ± 14.6 | 134.4 ± 11.6 |
| Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure | -0.58 ± 12.17 | -3.3 ± 9.4 |
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 6 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Nighttime Ambulatory Systolic Blood Pressure | 125.6 ± 13.9 | 125.4 ± 12.1 |
| Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure | -12.8 ± 14.1 | -13.4 ± 12.7 |
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Nighttime Ambulatory Systolic Blood Pressure | 123.1 ± 12.3 | 127.8 ± 10.7 |
| Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure | -17.1 ± 14.4 | -11.8 ± 12.2 |
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 8 weeks
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Nighttime Ambulatory Diastolic Blood Pressure | 82.5 ± 12.4 | 81.5 ± 8.4 |
| Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure | -0.44 ± 10.17 | -2.5 ± 7.3 |
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 6 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Nighttime Ambulatory Diastolic Blood Pressure | 75.8 ± 10.8 | 75.5 ± 9.2 |
| Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure | -7.4 ± 10.4 | -9.0 ± 8.0 |
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 12 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Mean Nighttime Ambulatory Diastolic Blood Pressure | 72.8 ± 8.2 | 77.4 ± 7.8 |
| Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure | -10.8 ± 9.7 | -7.6 ± 8.1 |
Change from Baseline in mean office SBP to 6 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| mean office SBP | 145.7 ± 14.3 | 146.1 ± 16.4 |
| Change from Baseline in mean office SBP to 6 Months | -14.7 ± 15.7 | -12.9 ± 15.6 |
Change from Baseline in mean office SBP to 12 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| mean office SBP | 147.8 ± 15.1 | 147.9 ± 18.5 |
| Change from Baseline in mean office SBP to 12 Months | -13.2 ± 16.6 | -11.0 ± 15.3 |
Change from Baseline in mean office DBP to 8 Weeks
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| mean office DBP | 97.3 ± 10.9 | 97.0 ± 9.4 |
| Change from Baseline in mean office DBP to 8 Weeks | -1.1 ± 8.8 | -3.5 ± 7.6 |
Change from Baseline in mean office DBP to 6 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| mean office DBP | 89.7 ± 10.5 | 90.4 ± 9.4 |
| Change from Baseline in mean office DBP to 6 Months | -8.4 ± 9.5 | -10.0 ± 9.0 |
Change from Baseline in mean office DBP to 12 Months
| mmHg | Sham Control Arm | Treatment Arm: |
|---|---|---|
| mean office DBP | 88.5 ± 11.5 | 91.0 ± 11.0 |
| Change from Baseline in mean office DBP to 12 Months | -9.6 ± 11.0 | -9.4 ± 9.4 |
Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sham Control Arm | 0/56 (0%) | 9/56 (16.1%) | 42/56 (75%) |
| Treatment Arm: | 0/50 (0%) | 7/50 (14%) | 41/50 (82%) |
| Event | Sham Control Arm | Treatment Arm: |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/56 | 2/50 |
| Abdominal abscessInfections and infestations | 0/56 | 1/50 |
| Appendicitis perforatedInfections and infestations | 0/56 | 1/50 |
| Post procedural haematomaInjury, poisoning and procedural complications | 0/56 | 1/50 |
| Urethral stenosisRenal and urinary disorders | 0/56 | 1/50 |
| AneurysmVascular disorders | 0/56 | 1/50 |
| HaematomaVascular disorders | 0/56 | 1/50 |
| Hypertensive crisisVascular disorders | 0/56 | 1/50 |
| Vascular pseudoaneurysmInjury, poisoning and procedural complications | 1/56 | 0/50 |
| Haemoglobin decreasedInvestigations | 1/56 | 0/50 |
| Event | Sham Control Arm | Treatment Arm: |
|---|---|---|
| HeadacheNervous system disorders | 7/56 | 11/50 |
| Post procedural haematomaInjury, poisoning and procedural complications | 4/56 | 6/50 |
| HaematomaVascular disorders | 2/56 | 5/50 |
| Glomerular filtration rate decreasedInvestigations | 5/56 | 2/50 |
| Back painMusculoskeletal and connective tissue disorders | 5/56 | 2/50 |
| HypertensionVascular disorders | 5/56 | 3/50 |
| NasopharyngitisInfections and infestations | 4/56 | 2/50 |
| Oedema peripheralGeneral disorders | 1/56 | 3/50 |
| Oedema peripheralGeneral disorders | 3/56 | 1/50 |
| Blood pressure increasedInvestigations | 3/56 | 2/50 |
| Age, Continuous(years) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Mean | 53.8 ± 11.0 | 54.4 ± 11.5 | 54.1 ± 11.3 |
| Sex: Female, Male(Participants) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Female | 10 | 18 | 28 |
| Male | 40 | 38 | 78 |
| Race and Ethnicity Not Collected(Participants) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Belgium | 1 | 1 | 2 |
| United Kingdom | 7 | 9 | 16 |
| France | 7 | 6 | 13 |
| Germany | 28 | 30 | 58 |
| Netherlands | 4 | 4 | 8 |
| Ireland | 2 | 2 | 4 |
| United States | 1 | 4 | 5 |
| eGFR(mL/min per 1.73 m^2) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Mean | 85.8 ± 14.0 | 85.9 ± 13.0 | 85.8 ± 13.4 |
| Diabetes (type 2)(Participants) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Count of participants | 2 | 5 | 7 |
| Smoking (current)(Participants) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Count of participants | 8 | 3 | 11 |
| Peripheral vascular occlusive disease(Participants) | Treatment Arm: | Sham Control Arm | Total |
|---|---|---|---|
| Count of participants | 1 | 1 | 2 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Jan 2022, 40 months.
Results were first posted in Oct 2024, 2 years 8 months after primary completion.
Of 15 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 40 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ethanol
Ablative Solutions, Inc.